'Rapid' path for Curis' lead leukemia drug hits road­block with par­tial clin­i­cal hold af­ter pa­tient death

A pa­tient has died in a Phase I/IIa tri­al of Curis’ lead drug af­ter ex­pe­ri­enc­ing rhab­domy­ol­y­sis,  “among sev­er­al con­di­tions.” As a re­sult, FDA has slapped a par­tial clin­i­cal hold on the study.

The hold could throw the biotech’s plans for a po­ten­tial “rapid reg­u­la­to­ry path” of the drug in­to ques­tion. Just six weeks ago, Curis said it ex­pect­ed to meet with the FDA to dis­cuss the reg­is­tra­tional route for emavusert­ib as a monother­a­py in the first half of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER